Project Grant HT94252310209
Award Date 4/1/23
Completion Date 5/31/27
Dollars Obligated $825K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Spain
Similar Awards
- The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
- The Department of the Army Medical Command awarded a $576,001 Project Grant to Cold Spring Harbor Laboratory to support research titled "Role of the Tumor Neuroenvironment in Prostate Cancer Metastasis." The two-year award running from August 1, 2022 to July 31, 2024 will fund research investigating the role of the tumor microenvironment in prostate cancer metastasis. This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program...
- This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
- The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
- This federal Project Grant award of $1,782,155 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Mayo Clinic to identify novel drug targets for lethal prostate cancer using liquid biopsy. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative medical solutions to critical health challenges. The award, with a performance period from April 1,...
- This $1,460,695 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the "Development and Validation of an Epigenomic Landscape and Novel Immunotherapy in Prostate Cancer Disparities" at The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. over the period of September 1, 2025 to August 31, 2028. The project aims to transform healthcare for military service members, veterans, and...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded $1.28M to the Institute of Cancer Research: Royal Cancer Hospital through the Military Medical Research and Development program (CFDA 12.420) beginning September 15, 2026 and concluding September 14, 2030. The project, titled "Targeting Myeloid Chemotaxis to Improve Clinical Outcomes from Radioligand Therapy in Advanced Prostate Cancer," delivers advanced biomedical research and development services focused on...
- Federal Grant Award Summary Beckman Research Institute of the City of Hope received a $2.136 million Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2028. The award supports developmental therapeutics research and the investigation of potential treatment strategies targeting RALBP1 (Retinoid-binding Protein 1) for castration-resistant prostate carcinoma. This...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $749,996 to the Institute of Cancer Research: Royal Cancer Hospital (The) on August 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) for the project "BAK-LOSS Lethal Prostate Cancer: Uncovering Therapeutic Vulnerabilities to Deliver New Treatments and Improve Clinical Outcomes." The four-year award, extending through July 31, 2029, supports research conducted in Great...
- This Project Grant award of $472,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of California, Los Angeles (UCLA) to investigate targeting TROP2-mediated ferroptosis as a new therapy for advanced prostate cancer. The project aims to transform healthcare for military service members, veterans, and the broader public by developing novel diagnostic tools, therapeutic interventions, and clinical...